Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TiGenix

- PMLiVE

NICE turns down CDF drug Adcetris in draft guidance

Takeda’s treatment for Hodgkin’s lymphoma not seen to be cost-effective

Brextinction

Evolution predicts tragic consequences from the UK's choice

EU flag

EU proposes reforms to make first-in-human trials safer

New guideline revision paper “takes into account lessons learnt” from fatal Bial trial

- PMLiVE

EU clears AZ’s FDA-rejected diabetes combination

Approval of two-drug therapy Qtern presents first-to-market advantage in Europe

Bristol-Myers Squibb (BMS) building

Opdivo moves closer to head and neck cancer approval

Possible US verdict by November for BMS’ ‘breakthrough’ SCCHN therapy

- PMLiVE

Celgene’s Revlimid cleared for aggressive lymphoma type in EU

Analysts anticipate sales of up to $10bn for the newly-expanded drug in coming years

- PMLiVE

Takeda partners with Marvel for IBD superheroes

Will work with the entertainment firm's content marketing agency

- PMLiVE

EMA: ‘business as usual’ – for now – after Brexit

And says it will be up to remaining EU members to decide on its future location

- PMLiVE

AZ gets EU green light for new antibiotic Zavicefta

EMA approves combination drug for treatment of multidrug resistant infections

- PMLiVE

Takeda hands back rights to two Amgen drugs

Returns pain and ovarian cancer candidates but will continue with collaboration

- PMLiVE

UK pharma faces ‘immediate challenges’ following Brexit

Life science sector awaits fallout from vote to leave the European Union

- PMLiVE

Industry welcomes European diagnostics regulations

Trade bodies say they will support greater use of personalised medicines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links